Welcome to our blog! This is where we share a bit more – insights, updates, and thoughts from Genovis. Take a look around and see what you find.
Search post
Category
Researchers at the University of Geneva led by Davy Guillarme has used a novel form of HPLC column, based on wide-pore hybrid silica bonded with amide ligand, and developed an HILIC analytical workflow for characterization of biopharmaceuticals. The scientists used FabRICATOR to fragment trastuzumab to subunits and studied the fragments using the new column with HILIC separation.…
Genovis expands the protease portfolio with GingisREX - a new enzyme with unique specificity for arginine residues. The GingisREX protease can be used for peptide mapping, protein sequencing and post-translational modification analysis using mass spectrometry. Press release Read more about GingisREX
New references are out using Genovis enzymes to study antibody glycation, pairing of high-mannose glycans and ADC characterization using CE-MS.
The cooperation agreement will provide Genovis with access to Alphalyse’s expertise in mass spectrometry while Alphalyse will have the opportunity to offer its customers analyses based on Genovis’ unique enzymes for antibodies and other pharmaceutical proteins.
To develop an antibody based PET imaging for detection of amyloid beta in mouse models, Sehlin and colleagues at the Rudbeck Laboratory in Uppsala, Sweden, used Fabricator to generate F(ab')2 fragments. In the study, published in Nature Communications, Sehlin et al. generated F(ab')2 fragments using FabRICATOR of an amyloid beta specific antibody and conjugated this to a transferrin receptor…
Genovis is launching a further development of GingisKHAN® that will be marketed under the name GingisKHAN®Fab kit. The product will be presented at the conference Antibody Engineering & Therapeutics in San Diego next week.
The Board of Directors of Genovis AB (publ) has decided to publish Q3 2015 report ahead of schedule.
For the Group, the reorganization will entail cost and capital expenditure savings of approximately SEK 6 million over a 12-month period. All intangible and tangible assets have been transferred to the Parent Company, which decided to sell the intellectual property rights behind the Nanomotus project to the inventors against future royalties.
The production of antibody-based therapeutics requires careful monitoring of quality attributes. Researchers at Amgen developed a technology to model and monitor the high-mannose content of the antibody in real-time using FabRICATOR digestion (Zupke et al. 2015).
The production of antibody-based therapeutics requires careful monitoring of quality attributes. Researchers at Institute Pasteur in collaboration with LFB Biotechnologies have used FabRICATOR to monitor important quality attributes of a therapeutic antibody, directly on the cell culture supernatant (Henninot et al. 2015).
We like to introduce FragIT Z – the immobilized version of FabRICATOR Z. Digest your mouse IgG2a more rapidly without having to remove the enzyme from the final preparation. For separation of the generated antibody domains we also offer the convenient FragIT Z Kit which enables rapid isolation of F(ab’)2 and Fc. Read more about…
Our enzymes are used frequently for studying important quality attributes of antibody-based biotherapeutics. To help you find the reference of interest we developed an Enzyme Reference Tool that organizes all papers published using our products. With this tool you can filter by quality attribute, enzyme used, type of antibody molecule and technology. Follow this link and try it…